Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.
Checkpoint Therapeutics, Inc. announced that the U.S. FDA approved its drug UNLOXCYT™ (cosibelimab-ipdl) in December 2024, making it the first and only anti-PD-L1 treatment for adults with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback